Clinical Trials Browser

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07102381 2026-03-12

EmpowHER 208

Phase 2 Recruiting

125 enrolled

Breast

Breast Neoplasms

NCT06695845 2026-02-25

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Phase 2 Recruiting

200 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Esophageal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07405476 2026-02-12

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Phase 2 Not yet recruiting

38 enrolled

Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT07176312 2026-02-04

ZANGEA

Phase 2 Recruiting

80 enrolled

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Phase 2 Recruiting

20 enrolled

Breast

Breast Neoplasms

NCT07296705 2025-12-22

HARBOR

Phase 2 Recruiting

25 enrolled

Genitourinary

Muscle Invasive Bladder Cancer (MIBC)

Clinical Trials

I-SPY

EmpowHER 208

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

ZANGEA

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

HARBOR